The UWI Regional Headquarters, Jamaica, W.I., Tuesday, November 17, 2026 — Researchers from The University of the West Indies (The UWI) have contributed to a landmark international study that could transform hypertension management in resource-constrained settings worldwide. Through their participation in the Caribbean and South American Team-Based Strategy to Control Hypertension (CATCH) Trial, investigators from the University's Caribbean Institute for Health Research (CAIHR) and the Department of Community Health and Psychiatry at the Mona Campus helped generate findings published in the prestigious Journal of the American Medical Association (JAMA).
The findings are particularly significant for the Caribbean, where hypertension remains a leading contributor to heart disease, stroke, kidney disease, dementia and premature death. The study provides compelling evidence that single-pill combination therapy merged with team-based care can substantially improve blood pressure outcomes, offering a practical and scalable approach for Caribbean governments and health systems seeking to reduce the region's growing burden of cardiovascular disease.
Professor Marshall Tulloch-Reid, Professor of Epidemiology and Endocrinology and Director of CAIHR, was Jamaica's Principal Investigator for the study. Commenting on the research, he noted, “We are pleased to be part of this international team of investigators who want to make a difference in hypertension management worldwide and collaborate with the leadership and staff of the Health Departments and the National Health Fund to execute this ground-breaking study. This is the largest study to demonstrate the long-term benefit of single-pill combination blood pressure tablets on blood pressure control and reflects CAIHR's commitment to engaging in research in the Caribbean that can have global impact.”
In Jamaica, where almost half of the adult population is estimated to have hypertension and only about one-fifth achieve adequate blood pressure control, the findings offer a practical, evidence-based intervention that can be delivered through existing primary healthcare systems. In 2020, the National Health Fund estimated expenditure of more than J$1.4 billion on subsidised hypertension medications, underscoring the need for more effective approaches to disease management and cardiovascular disease prevention.
The CATCH Trial enrolled 1,706 adults with uncontrolled hypertension across 40 primary care clinics in Jamaica and Colombia. Participants were randomly assigned to receive either standard care or an
intervention combining single-pill medications with coordinated team-based care involving physicians, nurses, community health workers, health coaching and home blood pressure monitoring.
After 18 months, participants receiving the intervention achieved substantially better outcomes. The study recorded a 10-mmHg difference in average blood pressure between the intervention and standard-care groups. Nearly 70% of participants receiving the intervention achieved blood pressure levels below 130/80 mmHg, compared with 30% in the usual-care group. No difference in serious side effects was observed, demonstrating that the strategy was both safe and effective.
The intervention was implemented within Jamaica's public primary healthcare system using existing service delivery structures. Government-run pharmacies dispensed medications, and members of the primary healthcare team delivered care under routine practice conditions. Results were consistent across urban and rural settings and did not differ significantly between Jamaica and Colombia, demonstrating the model's potential for implementation across diverse healthcare environments.
The findings provide strong evidence for the adoption of single-pill combination therapy and team-based care as an effective strategy for improving hypertension management across the Caribbean. They also demonstrate that a practical, scalable and safe intervention can achieve sustained improvements in blood pressure control across diverse healthcare settings worldwide, offering a model for reducing the global burden of cardiovascular disease.
The CATCH Trial was funded by the United States National Heart, Lung, and Blood Institute, National Institutes of Health.
Disclaimer
This article was posted in its entirety as received by SKNVibes.com. This media house does not correct any spelling or grammatical error within press releases and commentaries. The views expressed therein are not necessarily those of SKNVibes.com, its sponsors or advertisers